300942 易瑞生物
2025/09 - 九个月2024/122023/122022/122021/12

盈利能力分析
净资产收益率 ROE (%)2.0281.993-20.3888.68931.665
总资产报酬率 ROA (%)1.2271.217-14.0156.81426.200
投入资产回报率 ROIC (%)1.3181.316-15.4777.65929.590

边际利润分析
销售毛利率 (%)64.30570.62849.92956.50671.632
营业利润率 (%)8.9819.349-68.98714.28344.897
息税前利润/营业总收入 (%)13.72012.285-71.06912.57745.693
净利润/营业总收入 (%)10.1317.411-72.79812.03439.574

收益指标分析
经营活动净收益/利润总额(%)23.35770.94544.059138.51192.300
价值变动净收益/利润总额(%)-9.196-20.20530.4192.8203.606
营业外收支净额/利润总额(%)1.867-6.4801.404-3.395-0.089

偿债能力分析
流动比率 (X)5.1594.9465.3873.3765.731
速动比率 (X)4.7734.6805.1582.8725.132
资产负债率 (%)38.55540.27837.42524.77717.869
带息债务/全部投入资本 (%)33.17635.66629.32710.9621.914
股东权益/带息债务 (%)199.573178.619234.117763.4644,870.858
股东权益/负债合计 (%)158.977148.061167.253303.659458.756
利息保障倍数 (X)3.0033.50564.635-10.16754.695

营运能力分析
应收账款周转天数 (天)140.931136.622113.35747.41248.002
存货周转天数 (天)200.355196.462186.842117.164165.069